RECURSION PHARMACEUTICALS, INC.

Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX), a clinical-stage company focused on AI-enabled drug discovery, announced its participation in three upcoming investor conferences: the Jefferies Global Healthcare Conference, the Evercore 9th Annual Healthcare Conference, and Citi’s 2026 Global Healthcare Conference. Webcasts of these events will be accessible through the company's Investor Relations website.

Recursion Pharmaceuticals reported a net loss of $(131.0) million for the second quarter of 2026, an improvement compared to $(171.9) million in the same period last year. However, total revenue significantly decreased to $7.67 million from $19.22 million year-over-year. The company's cash and cash equivalents were $545.68 million as of June 30, 2026, and it expects existing cash to fund operations for at least the next 12 months. Key operational updates include the acquisition of RE Ventures I and the sale of Exscientia GmbH.

Recursion Pharmaceuticals reported a net loss of $131.0 million for Q2 2026, an improvement from the $171.9 million loss in Q2 2025, despite a decrease in total revenue to $7.7 million. The company also announced a significant milestone with Genentech advancing the first neuroscience target into an early discovery program, validating Recursion's AI-native platform. Additionally, Recursion lowered its full-year 2026 cash operating expense guidance to less than $375 million and provided updates on its clinical pipeline, including upcoming data presentations for REC-4881 and the initiation of a Phase 1/2 trial for REC-7735.

Recursion Pharmaceuticals, Inc. announced its participation in two upcoming investor conferences. The company will attend the Bank of America 2026 SMID Cap Executive Insights Event on August 11, 2026, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Webcasts for these events will be accessible through the investor relations section of Recursion's website.

Recursion Pharmaceuticals announced the grant of inducement restricted stock unit (RSU) awards covering 3,234,866 shares of its Class A common stock to 24 new employees. These awards were approved by the Compensation Committee on July 27, 2026, under the company's 2024 Inducement Equity Incentive Plan. The grants serve as a material inducement for the employees' commencement of employment, with vesting tied to continued employment.

Recursion Pharmaceuticals, Inc. announced it will provide business updates and report its second quarter 2026 financial results on Wednesday, August 5, 2026, before the financial markets open. The company will host an earnings call on the same day at 8:00 AM ET, which will be broadcast live on its X, LinkedIn, and YouTube accounts. Investors and the public will have the opportunity to submit questions for the company.

Recursion Pharmaceuticals announced that its Compensation Committee approved inducement restricted stock unit (RSU) awards for 33 new employees. These awards cover an aggregate of 2,991,840 shares of Class A common stock under the company's 2024 Inducement Equity Incentive Plan. The grants serve as a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4), and will vest over time subject to continued employment.

Recursion Pharmaceuticals reported a reduced net loss of $(117.5) million for Q1 2026, an improvement from $(202.5) million in Q1 2025. Total revenue decreased to $6.47 million from $14.75 million year-over-year, while operating costs and expenses also saw a substantial reduction. The company also established a new at-the-market offering for up to $300 million of Class A common stock.

Recursion Pharmaceuticals reported a reduced net loss of $117.5 million for Q1 2026, down from $202.5 million in Q1 2025, alongside a significant decrease in net cash used in operating activities to $81.1 million. The company maintained a strong cash position of $665.2 million, extending its runway into early 2028. While revenue decreased to $6.5 million, R&D and G&A expenses saw substantial reductions. The company also provided positive updates on its clinical pipeline, including favorable early data for REC-1245, strong Phase 2 efficacy signals for REC-4881 with FDA engagement, and the dosing of the first patient in the Phase 1 study for REC-4539.

Recursion Pharmaceuticals, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 17, 2026. Stockholders as of the April 21, 2026 record date are eligible to vote on key proposals. These include the election of two Class II directors, an advisory vote on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026.